Modality
Cell Therapy
MOA
USP1i
Target
SGLT2
Pathway
Epigenetic
Breast CaGISTDravet
Development Pipeline
Preclinical
Mar 2018
→ Dec 2025
PreclinicalCurrent
NCT08826857
2,860 pts·Dravet
2024-04→2025-12·Completed
NCT05598730
2,560 pts·GIST
2018-03→TBD·Not yet recruiting
5,420 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-12-124mo agoInterim· Dravet
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
Preclinical
Not yet…
Preclinical
Complet…
Catalysts
Interim
2025-12-12 · 4mo ago
Dravet
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08826857 | Preclinical | Dravet | Completed | 2860 | BodyWt |
| NCT05598730 | Preclinical | GIST | Not yet recr... | 2560 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Tirarapivir | United Therapeutics | Approved | SGLT2 |